Conditions: Atopic Dermatitis
Keywords: Eczema
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 78
Healthy volunteers: no

Brief summary:
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).

The secondary objective of the study is to explore the immunogenicity and efficacy of dupilumab in pediatric patients with moderate-to-severe AD (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).

Detailed description:

Arms:
arm 1: Cohort 1 will receive dupilumab dosing regimen 1 arm 2: Cohort 2 will receive dupilumab dosing regimen 2

Interventions: intervention 1: Dupilumab
Intervention descriptions: intervention 1: None

Protocol document: